About Us
Samsung Epis Holdings supports its subsidiaries, Samsung Bioepis and Epis NexLab, in growing into global leaders in the biopharmaceutical market through innovative research and development and strategic investment.
Established in 2012, Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company.
Epis NexLab dedicated to developing biotechnological platforms for future growth, the company plans to develop various new drug candidates by transforming highly scalable core technologies into platforms.
Its main business areas include reviewing the development of various core technology platforms related to peptides. Through these efforts, the company aims to identify new growth drivers in the biopharmaceutical field and grow into a leading biotechnology company in next-generation therapeutic technologies.
Business Introduction
Epis NexLab plans to transform highly scalable core technologies into platforms and develop various new drug candidates based on a biotech model. It also aims to pursue license-out or joint development opportunities with global pharmaceutical companies. 'The biotechnology platform serves 'as a foundational technology that enables the effective and rapid generation of multiple drug candidates. It is not limited to specific drugs or indications, so it can be applied to a wide range of disease areas with high scalability.
Biotech Business Model
(Bio Technology Platform Development)
Platform Development
- In-house design/development
- Collaboration and investment in domestic and global
Drug Candidate Discovery
- Identification of medical needs
- Application to target disease areas
Securing Revenue
- Joint development and License-out of drug candidates
Business Areas
Epis NexLab is focusing on securing key platform technologies for the future, and is reviewing various research and development areas from multiple perspectives.
In the mid- to long-term, the company will focus on transforming peptide-related technologies into development platforms.
Peptide Technology Platform
- A differentiated technology platform based on peptides (amino acid compounds) that enhances drug delivery and functionality
- Discovery of new drug candidates for major diseases, such as obesity, glycosuria, and cancer